Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perazine for schizophrenia.

S Leucht1, B Hartung

  • 1Klinikum rechts der Isar der TU-München, Klinik für Psychiatrie und Psychotherapie, Ismaningerstr. 22, München, Germany, 81675. Stefan.Leucht@lrz.tu-muenchen.de

The Cochrane Database of Systematic Reviews
|April 21, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[(Failed) Intubation during emergency coniotomy by the emergency physician].

Die Anaesthesiologie·2026
Same author

Cannabis in road traffic - a retrospective analysis to identify possible cut-off-values.

Forensic science, medicine, and pathology·2025
Same author

Parking behaviour under the influence of alcohol.

International journal of legal medicine·2023
Same author

Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders.

Translational psychiatry·2022
Same author

A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2021
Same author

Efficacy, acceptability, and tolerability of all available treatments for insomnia in the elderly: a systematic review and network meta-analysis.

Acta psychiatrica Scandinavica·2020
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Limited trials suggest perazine may be effective for schizophrenia, but more research is needed. While not causing more general adverse events than placebo, its use requires careful consideration due to potential extrapyramidal side effects.

Area of Science:

  • Psychiatry
  • Clinical Pharmacology

Background:

  • Perazine is a phenothiazine derivative used for schizophrenia treatment.
  • It is reputed to have a low incidence of extrapyramidal adverse effects.
  • Its clinical use is currently limited to specific European countries.

Purpose of the Study:

  • To evaluate the efficacy and safety of perazine in treating schizophrenia and schizophrenia-like psychoses.

Main Methods:

  • A systematic review of randomized controlled trials (RCTs) was conducted.
  • Searches included major bibliographic databases and trial registries.
  • Data extraction and analysis followed Cochrane Schizophrenia Group guidelines.

Main Results:

  • Six RCTs with 288 participants were included.

Related Experiment Videos

  • Perazine showed potential benefit over placebo in one trial, but mental state outcomes were largely similar.
  • Adverse event data were limited, with some indication of increased antiparkinsonian medication use compared to placebo.

    • Conclusions:

    • The available evidence from RCTs on perazine is insufficient to draw firm conclusions.
    • Larger, well-designed trials are necessary to clarify its efficacy and safety profile.
    • Perazine may have a similar risk of extrapyramidal side-effects as some atypical antipsychotics.